The log-rank P values were all less than 0.05, suggesting that patients with high expression of PAK1 and HDAC6/10 had higher mortality rates than those with low expression, indicating the potential of PAK1 and HDAC10 as therapeutic targets for breast cancer. Here, PAK1 is linked to breast carcinoma.